AyvaciER, MinhajuddinA, ElmoreJS, et al.Treatment of adolescent depression: Comparison of psychiatric and pediatric settings at an academic medical center using the VitalSign6 application. J Child Adolesc Psychopharmacol, 2024; 34(2):80–88; doi: 10.1089/cap.2023.0041
2.
KanuAA, JohnstonMM, PoweleitEA, et al.Influence of CYP2D6 metabolizer status on risperidone and paliperidone tolerability in children and adolescents. J Child Adolesc Psychopharmacol, 2024; 34(1):34–41; doi: 10.1089/cap.2023.0046
MalikS, VermaP, RuañoG, et al.Pharmacogenetics in child and adolescent psychiatry: Background and evidence-based clinical applications. J Child Adolesc Psychopharmacol, 2024; 34(1):4–20; doi: 10.1089/cap.2023.0074
5.
NooraeenS, CroarkinPE, GeskeJR, High probability of gene-drug interactions associated with medication side effects in adolescent depression: Results from a randomized controlled trial of pharmacogenetic testing. J Child Adolesc Psychopharmacol, 2024; 34(1):28–33; doi: 10.1089/cap.2023.0043
6.
PowersJH, WuM, PalumboM, et al.Guanfacine for the treatment of ADHD in children and adolescents with Down syndrome: A retrospective chart review. J Child Adolesc Psychopharmacol, 2024; 34(2):95–103; doi: 10.1089/cap.2023.0069
7.
ThomRP, CanalesC, TresvallesM, et al.Neuroimaging research in William's syndrome: Beginning to bridge the gap with clinical care. Neurosci Biobehav Rev, 2023; 153:105364; doi: 10.1016/j.neubiorev.2023.105364
Weinschutz MendesH, NeelakantanU, LiuY, et al.High-throughput functional analysis of autism genes in zebrafish identifies convergence in dopaminergic and neuroimmune pathways. Cell Rep, 202328;42(3):112243; doi: 10.1016/j.celrep.2023.112243
